CARM Carisma Therapeutics, Inc.
Healthcare$0.00+0.00%ClosedMarket Cap: $4,185
As of 2026-05-26
Valuation
P/E (TTM)
0.18
PEG
0.00
P/B
-0.00
P/S
0.00
EV/EBITDA
-0.15
DCF Value
$-78.51
FCF Yield
-535603.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.1%
Operating Margin
20.6%
Net Margin
15.3%
ROE
-28.9%
ROA
122.7%
ROIC
-10330.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $45.3M | 100.0% | $43.8M | $44.7M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-5.8M | $-9.8M | $— | — |
| Q1 null | $3.7M | 100.0% | $-9.3M | $-9.3M | $— | — |
| Q4 null | $3.7M | 81.7% | $-17.9M | $-17.6M | $— | — |
| FY null | $19.6M | -204.0% | $-62.2M | $-60.5M | $— | — |
| Q3 null | $3.4M | 100.0% | $-13.1M | $-12.7M | $— | — |
| Q2 null | $9.2M | -66.4% | $-11.7M | $-11.2M | $— | — |
| Q1 null | $3.4M | -414.0% | $-19.5M | $-19.0M | $— | — |
| Q4 null | $4.3M | 51.4% | $-22.4M | $-21.0M | $— | — |
| FY null | $14.9M | -396.8% | $-88.7M | $-86.9M | $— | $0.36 |
| Q3 2023 | $3.8M | -410.9% | $-22.3M | $-21.4M | $-0.53 | — |
| Q2 2023 | $3.6M | -420.2% | $-21.0M | $-19.9M | $-0.49 | — |